A Role for Androgens in Epithelial Proliferation and Formation of Glands in the Mouse Uterus

Citation for published version:
Simitsidellis, I, Gibson, DA, Cousins, FL, Esnal-Zufiaurre, A & Saunders, PT 2016, 'A Role for Androgens in Epithelial Proliferation and Formation of Glands in the Mouse Uterus', Endocrinology, pp. en20152032. https://doi.org/10.1210/en.2015-2032

Digital Object Identifier (DOI):
10.1210/en.2015-2032

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Endocrinology

Publisher Rights Statement:
This article has been published under the terms of the Creative Commons Attribution License (CC-BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
A Role for Androgens in Epithelial Proliferation and Formation of Glands in the Mouse Uterus.

Ioannis Simitsidellis¹, Douglas A Gibson¹, Fiona L Cousins¹,², Arantza Esnal-Zufiaurre¹, and Philippa TK Saunders¹

¹ MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, 47 Little France Cres, EH16 4TJ, Edinburgh, UK

The endometrium consists of stromal and epithelial compartments (luminal and glandular) with distinct functions in the regulation of uterine homeostasis. Ovarian sex steroids, namely 17β-estradiol (E₂) and progesterone (P₄), play essential roles in modulating uterine cell proliferation, stromal-epithelial cross-talk and differentiation in preparation for pregnancy. The impact of androgens on uterine function remains poorly understood. The current study investigated the impact of the non-aromatizable androgen dihydrotestosterone (DHT) on mouse endometrial function. Ovariectomized female mice were given a single subcutaneous injection (short treatment) or 7 daily injections (long treatment) of vehicle alone (5% ethanol, 0.4% methylcellulose) or vehicle with the addition of 0.2 mg DHT (n=8/group) and a single injection of Bromodeoxyuridine (BrdU) 2 hours prior to tissue recovery.

Treatment with DHT increased uterine weight, the area of the endometrial compartment and immunoexpression of the androgen receptor (AR) in the luminal and glandular epithelium. Treatment-dependent proliferation of epithelial cells was identified by immunostaining for MKi67 and BrdU. Quantitative RT-PCR identified significant DHT-dependent changes in the concentrations of mRNAs encoded by genes implicated in the regulation of the cell cycle (Wee1, Ccnd1, Rb1) and stromal-epithelial interactions (Wnt4, Wnt5a, Wnt7a, Cdh1, Vcl, Igf1, Prl8, Prlr) as well as a striking impact on the number of endometrial glands.

This study has revealed a novel role for androgens in regulating uterine function with an impact on the glandular compartment of the endometrium. This previously unrecognised role for androgens has implications for our understanding of the role of androgens in regulation of endometrial function and fertility in women.

T he endometrium is a hormone-dependent multicellular tissue that consists of stromal and epithelial compartments. The stromal compartment contains mesenchymal fibroblasts, a well-developed vasculature and immune cells, while the epithelium is divided into a luminal and a glandular component, each with a distinct identity and role in reproductive physiology (1). Both compartments respond to hormonal cues in a coordinated spatial and temporal manner characterized by extensive cross-talk to regulate the development and homeostasis of the tissue (2–4).

While the impacts of estrogens on endometrial function have been extensively studied, androgens have only recently emerged as key players in the regulation of endometrial function. Analysis of circulating steroid hormone levels utilizing sensitive liquid chromatography-tandem mass spectrometry has revealed significant concentrations of androgens present throughout the menstrual cycle in women exceeding those of circulating estrogens (5).
Investigation of circulating androgen levels in cycling female mice reported detectable concentrations of the circulating testosterone metabolite 5α-dihydrotestosterone (DHT; 2.8 ± 0.4 pg/ml) during all phases of the estrous cycle, with concentrations peaking during proestrus and metestrus (6). In aging female mice, there is a significant increase of circulating DHT, with a mean value of 12.8 ± 0.6 pg/ml. To our knowledge there are no studies in the literature regarding the circulating levels of DHT during mouse pregnancy, however, there are several reports that androgen levels increase during pregnancy in women (reviewed in (7)). In women androgens appear to be ‘Goldilocks’ factors with both deficiency and excess contributing to pregnancy- and fertility-related disorders such as polycystic ovarian syndrome (8, 9), endometriosis (10) and recurrent pregnancy loss (11).

The effects of androgens are mediated via the androgen receptor (AR), a ligand-activated transcription factor that binds testosterone (T) and its metabolite 5α-dihydrotestosterone (DHT) with high affinity and specificity. In women, expression of AR in the endometrium is regulated both temporally and spatially during the normal menstrual cycle and detailed analysis of full-thickness uterine tissue sections identified endometrial stromal fibroblasts as a key targets for androgen action (12). Administration of antiprogestins in women and nonhuman primates induces upregulation of AR in the uterine epithelium, which may mediate the antiproliferative effects of these compounds (13). In the uteri of mice, quantitative in situ hybridization detected uniform labeling of Ar mRNA in all compartments, including the epithelium (14). A recent study reported nuclear stromal AR staining in the mouse uterus but AR was not detected in the luminal or glandular epithelium (15). A study using a transgenic mouse model of an androgen response element (ARE) construct fused to a luciferase reporter revealed strong AR activity in the uterus, with the antiandrogen bicalutamide inhibiting luciferase activity (16). Female global AR knockout (AR KO) mice are subfertile, with a neuroendocrine and ovarian phenotype accompanied by defects in uterine development (17).

Studies in female-to-male transsexuals have reported a negative impact of androgens on endometrial proliferation in response to long-term administration of testosterone, resulting in endometrial atrophy (18, 19). Treatment of primary human endometrial stromal cells with DHT also results in a significant reduction in both proliferation and apoptosis (12). Androgen-estrogen cross-talk has been implicated in the initiation and progression of endometrial cancers, with androgens acting in an antagonistic manner to the proliferative effects of estrogens, restricting endometrial carcinogenesis (reviewed in (20)). Wei et al. reported that the proliferative effects of E2 in the rat uterus were blocked by either the antiestrogen tamoxifen or the antiandrogen flutamide (21), suggesting a functional overlap between androgen and estrogen action in this rodent species. Microarray analysis of uteri recovered from ovariectomized mice after a single injection of DHT revealed time-dependent changes in the expression of genes involved in the regulation of cell division and organ development between 12 and 24 hours post injection (22).

Sex steroids have been shown to exert different effects in cell proliferation and apoptosis resulting from either acute or chronic stimulation (reviewed in (23, 24)). In the 1970s, Lee and colleagues recorded three phases of epithelial cell proliferation within the mouse uterus in response to continuous oral treatment with estrogen, characterized by pronounced uterine epithelial cell proliferation on days 2 and 3, basal proliferation on days 4 and 5 and a second wave of proliferation on days 19 and 20 (25, 26). Similar effects have been reported in prostate cancer cells in response to androgen treatment, characterized by an early proliferative response followed by a refractory period to androgen-induced proliferation (27). Taking into account this biphasic effect of androgens in controlling cell proliferation of target tissues, a short-term (24 hrs) and a long-term (7 days) treatment paradigm was selected to elucidate the impact of DHT on endometrial growth in a mouse model. Experiments were performed in ovariectomized mice to avoid the confounding impacts of endogenous ovarian hormones.

In the current study, we show that treatment with DHT has compartment-specific impacts on the immunohistochemical expression of AR, cellular proliferation and expression of cell-cycle regulators and epithelial growth factors resulting in an increase in the number of uterine glands. These striking findings identify a novel role for androgens in the regulation of endometrial homeostasis.

Materials and Methods

Animals and Treatments

Female C57BL/6J mice were purchased from Charles Rivers Laboratories and allowed to acclimate for a week with ad libitum access to food and water. Mice were maintained in accordance with UK legal requirements under licensed approval from the UK Home Office. Eight- to ten-week old female mice were ovarioctomized (ovx) by dorsal bilateral ovariectomy and allowed to recover for 7 days prior to treatment to deplete endogenous sex- steroid hormones. Surgery was performed under isoflurane anesthesia followed by a postoperative analgesic, buprenorphine (0.1 mg/kg) for pain management. Mice were randomly assigned into four treatment groups (n = 8/group, 32 in total). To explore the short-term and long-term impacts of androgens mice received either one (24 hrs group) or seven (7 days group) daily subcu-

The Endocrine Society. Downloaded from press.endocrine.org by [individualUser.displayName] on 22 March 2016 at 04:14. For personal use only. No other uses without permission. All rights reserved.
taneous injections of DHT (0.2 mg/mouse) or vehicle control (5% ethanol-0.4% methylcellulose). Two hours prior to being sacrificed, mice received an intra-peritoneal injection of 0.1 ml BrdU (25 mg/ml in PBS).

To measure the serum concentration of DHT after treatments, blood was collected via cardiac puncture and exsanguination from mice treated with VC (5% ethanol-0.4% methylcellulose) or DHT (0.2 mg/mouse) for 24 hrs (n = 4/group). Serum DHT concentrations were assayed using a commercially available mouse DHT ELISA kit (Amsbio, BioGenie; Cat. Number E03D0001 - Assay sensitivity: 1 pg/ml). Samples were assayed in duplicate and a standard curve was generated using a four parameter logistic curve fit (4-PL); sample DHT concentrations were interpolated from the standard curve. For analysis of tissues, one uterine horn was fixed in 4% neutral buffered formalin (NBF) for paraffin embedding, sectioning and histology while the other horn was kept in RNA Save at –80°C.

RNA Extraction and Reverse Transcription

Total RNA was extracted from homogenized mouse uterine tissue (20 mg/sample) using TriReagent and chloroform followed by RNeasy Mini Kit (Qiagen, UK) column isolation and elution as per the manufacturer’s instructions. RNA concentration and quality was measured using a Nanodrop® ND-1000 spectrophotometer (Nanodrop Technologies, USA) and the samples were standardized to 100 ng/μl in RNase-free water. Reverse transcription was performed using SuperScript VILO cDNA Synthesis Kit and Master Mix (Invitrogen, UK) as per the manufacturer’s instructions using a thermal cycler programmed at: 25°C for 10 minutes, 42°C for 60 minutes and 52°C for 5 minutes. Two negative controls (no enzyme control and no RNA control) and one positive control (mouse RNA positive control) were included for each set of RNA samples.

Quantitative RT-PCR Analysis

Quantitative PCR was performed using SuperMix with Premixed ROX dye (Invitrogen, UK), primer sets designed using the Roche Universal Probe Library Assay Design Centre (sequences in Table 1) purchased from Eurofins (MWG Operon) and probes from the Roche Universal Probe Library Mouse Set (Roche Applied Science, UK). Samples were assayed in duplicate and run on an ABI 7900 HT Fast Real Time PCR machine using the following cycling conditions: 95°C for 10 minutes then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Primer amplification efficiency was validated and analysis was performed using the relative standard curve method. Data were normalized to 18S and fold-change is expressed as the ratio of expression of each gene of interest in the treated groups vs the average of the VC groups (one for the 24 hrs and one for the 7 days time point respectively). Statistical analysis was performed using GraphPad Prism 6.0. Data are presented as mean±/SEM. Student’s t test was used for comparison between VC and DHT groups. Crite-

Immunohistochemistry and Immunofluorescence

Samples were fixed in 4% NBF overnight at room temperature, transferred in 70% ethanol and the tissues were processed for paraffin wax embedding. Transverse sections of 5 μm thickness were cut using a microtome (Leica RM2135) and the slides were incubated overnight at 55°C. For histology, the tissues were dewaxed, rehydrated and antigen retrieval was performed using citrate (0.01M citrate, pH 6.0) in a decloaking chamber followed by several blocking steps with serum from the species the secondary antibody was raised in, to avoid nonspecific binding and hydrogen peroxide was used to block endogenous peroxidase activity. Sections were incubated with the primary antibody diluted in serum blocking solution overnight at 4°C. Negative controls were included, in which the primary antibody was omitted to identify any nonspecific binding by the secondary antibody. The following day, detection was performed by using either a conjugated secondary antibody specific for the primary antibody or a polymer-based detection system (ImmPress, Vector Labs, UK). For chromogenic immunohistochemistry, DAB (Vector, UK) was used as a chromogen, while for immunofluorescence the Tyramide Signal Amplification system (Perkin Elmer, UK) was used as per the manufacturer’s instructions. Between incubations, washes were performed with TBS-Tween. Hematoxylin was used as a counterstain for immunohistochemistry and DAPI as a counterstain for immunofluorescence. Antibody information is provided in Table 1.

Image Acquisition and Stereology

For chromogenic immunohistochemistry images were acquired with a Provis AX70 microscope (Olympus Optical, London, UK) fitted with a Canon D56031 camera (Canon Europe, Amsterdam) while fluorescent images were acquired with a LSM 710 confocal microscope (Carl Zeiss, UK) and processed with the ZEN software (Carl Zeiss). Tissue surface area was measured using a Zeiss AXIO Imager A1 (Carl Zeiss, UK) while quantification of BrdU-positive epithelial cells and of the number of glands was performed by blinded manual counting by two independent investigators. For the calculation of cell density, sections were counterstained with DAPI and acquired images were analyzed using the image analysis software Fiji (28). In all cases, a minimum of two nonserial sections were used (n = 4–8/treat-

Table 1. Antibody Table

| Protein target            | Antibody | Supplier        | Catalogue number | Species raised in | Dilution |
|---------------------------|----------|-----------------|------------------|-------------------|----------|
| Androgen receptor         | AR       | Spring Bioscience | M4070            | Rabbit            | 1/300    |
| Bromodeoxyuridine         | BrdU     | Fitzgerald       | 20-BS17          | Sheep monoclonal  | 1/1000   |
| Marker of proliferation Ki67 | MK117   | Abcam           | Ab15580          | Rabbit polyclonal | 1/2000   |
| Forkhead box protein 2    | FOXA2    | Santa Cruz      | SC9187           | Goat polyclonal   | 1/3000   |

The Endocrine Society. Downloaded from press.endocrine.org by [individualUser.displayName] on 22 March 2016 at 04:14. For personal use only. No other uses without permission. All rights reserved.
ment group). Statistical analysis was performed using GraphPad Prism 6.0. Student’s t test was used for comparison between VC and DHT groups, with statistical significance for \( P < 0.05 \).

Unless otherwise stated all reagents for this study were purchased from Sigma-Aldrich.

**Results**

**Trophic effects of androgens in the mouse uterus**

In order to elucidate the actions of DHT in mouse uterine physiology, ovx mice were treated with either vehicle or DHT under a short- or long-term treatment regime (24 hrs and 7 days respectively). ELISA analysis of serum from mice injected with vehicle control or DHT 24 hrs previously had a mean DHT concentration of 180 pg/ml in the DHT group, while DHT concentrations in the control group were below the level of detection (<1 pg/ml) (Supplemental Figure 1). These results appear consistent with those of Zhang et al who previously demonstrated that ovx C57BL/6 female mice injected subcutaneously with 0.1 mg/mouse DHT, exhibit a peak of circulating DHT 1 hour post-injection (~14 ng/ml) which rapidly declines over the following 24 hrs (29).

The short-term treatment with DHT (24 hrs) induced a significant increase in uterine weight compared to vehicle which was further increased when treatment was extended to 7 days (Figure 1A, \( P < 0.001 \) at 7 days). The effect of DHT on uterine weight was accompanied by significant increase of total uterine surface area (Figure 1B), endometrial area (Figure 1C) and myometrial area (Figure 1D) at both time points. Analysis of cell density suggested the change in uterine size was due to an increase in cell numbers accompanied by a significant reduction in cell density at both time points (Figure 1E, F).

**Treatment with DHT induces epithelial AR expression in the mouse uterus**

Positive immunoexpression of AR was detected in the stromal compartment at both 24 hrs and 7 days in both vehicle and DHT-treated mice. DHT treatment induced expression of AR in the luminal and glandular epithelium at 24 hrs (Figure 2B) that was absent in vehicle groups at both time points (Figure 2A, C). In mice treated with DHT for 7 days, AR was detected in the stroma and the glandular epithelium but not the luminal epithelium (Figure 2D). Real-time PCR showed a significant decrease of AR mRNA after 7 days of DHT treatment compared to vehicle (Figure 2E). Investigation of the expression pattern of ER\( \alpha \) revealed no difference between vehicle and DHT treated-groups at both time points (Supplemental Figure 2).

**Treatment with DHT induces epithelial proliferation in the mouse uterus**

Immunofluorescence was performed with an antibody targeting the proliferation marker MKi67 that detects all cells in interphase or undergoing mitosis. Staining identified extensive proliferation of luminal and glandular epithelial cells after treatment with DHT at 24 hrs compared to vehicle (Figure 3A, B; white arrowheads). Only a small number of epithelial cells were positive for MKi67 in both vehicle- and DHT-treated groups after 7 days of treatment (Figure 3C, D; white arrowheads). The immunostaining for MKi67 in the stroma was minimal for all treatment groups. DHT induced a significant increase of MKi67 mRNA levels after 24 hrs of treatment compared to vehicle, while at 7 days there was no significant change between the two treatment groups (Figure 3E), consistent with MKi67 staining detected by immunofluorescence.

DNA incorporation of BrdU was used as a measure of the proliferative state of cells during the two hours prior to animal sacrifice. Staining with an anti-BrdU antibody revealed a limited number of positive epithelial cells in the vehicle-treated groups for both time points (Figure 4A, D). Treatment with DHT induced extensive proliferation of both the glandular and luminal epithelium at 24 hrs (Figure 4B). Very low proliferation was detected in the stromal compartment. This was also confirmed by assessment of the proliferation index of epithelial cells; there was a significant increase in the proliferation of luminal and glandular epithelial cells between the vehicle and DHT treatment groups at 24 hrs (Figure 4C). That was absent after 7 days (Figure 4D, E, F).

**DHT regulates genes necessary for proliferation, cell-cycle regulation and stromal-epithelial cross-talk in the mouse uterus**

Real-time PCR analysis identified dynamic changes in the expression of several genes associated with cell-cycle regulation and stromal-epithelial cross-talk following treatment with DHT.

**Weel** expression was significantly upregulated by DHT after 24 hrs, followed by a significant downregulation at 7 days (Figure 5A). **Ccnd1** expression was significantly increased by DHT at 24 hrs followed by a significant decrease after 7 days (Figure 5B). **Rb1** expression was significantly downregulated by DHT at both time points (Figure 5C).

**Wnt** signaling, involved in stromal-epithelial cross-talk in the uterus, was significantly affected by treatment with DHT. **Wnt4** expression was significantly downregulated after treatment with DHT for 24 hrs and 7 days (Figure 5D). **Wnt5a** mRNA concentration was significantly increased by DHT at both time points (Figure 5E), while
Figure 1. Treatment with DHT induces a trophic effect in the mouse uterus. Mice were ovariectomized and treated with vehicle control (VC) or DHT as described in the Materials and Methods section. (A) At 24 hrs there was a modest but significant increase in uterine wet
Wnt7a expression was downregulated by DHT only at 7 days (Figure 5F).

Cdh1, which is expressed in the uterine epithelium was significantly upregulated by DHT at both 24 hrs and 7 days (Figure 5G), while expression of the adherens junction component vinculin (Vcl) involved in intercellular adhesion and signaling displayed a significant upregulation by DHT at 24 hrs, with no significant change observed between vehicle and DHT at 7 days (Figure 5H). Expression of the putatively androgen-regulated epithelial growth factor Igf1 was significantly upregulated by DHT at both time points compared to vehicle treatments, reaching an average 10-fold increase at 7 days (Figure 5I). Prlr, whose role has been reported in gland formation in the mouse uterus, was significantly upregulated more than 20-fold at both time points (Figure 5J), with a similar pattern observed for its receptor (Prlr, Figure 5J). Furthermore, expression of the epithelial growth factors Fgf7 (Figure 7L) and Hgf (Figure 7M) was significantly altered after treatment with DHT. The transcription factor Foxa2, which is exclusively expressed in uterine glands exhibited a trend for an increase after DHT treatment at 24 hrs (P = .14) but the changes at both time points didn’t reach statistical significance (Figure 5K).

A role for androgens in regulating gland formation in the mouse uterus

Histological examination of uterine sections at 7 days suggested more glands with DHT treatment. FOXA2 is a transcription factor expressed exclusively in the glands in the mouse uterus and FOXA2 immunohistochemistry was performed to quantify the number of glands between the treatment groups (Figure 6A, B). A significant increase in the total number of glands was observed with DHT compared to vehicle treatment verifying the qualitative observations (Figure 6C). To compare the effect of DHT with that with E2 in glandular expansion, ovx mice treated with an E2 pellet for a week were used as a comparator. Staining for FOXA2 and quantification of glands demonstrated fewer glands in the E2 group compared to the DHT-treated group accompanied by a weaker staining pattern (Supplemental Figure 3A, D). Real-time PCR identified a significant reduction in Foxa2 expression levels between E2 and DHT-treated groups (Supplemental Figure 3).

Discussion

In this study, we have demonstrated that androgens induce epithelial proliferation resulting in an increased numbers of endometrial glands in the adult mouse uterus. Uterine glands are essential for uterine receptivity and implantation and secrete factors which are necessary for the survival and development of the conceptus. Our results suggest that homeostatic balance of androgens and the local steroidogenic environment could be important physiological drivers of gland formation during endometrial remodeling in early pregnancy. Animal models in which uterine gland development is disrupted, exhibit compromised fertility and altered expression of decidualization factors (30, 31), highlighting the potential for prospective therapeutic targeting of androgen signaling in the uterus for fertility-associated disorders (32). Although a trophic effect of androgens in the rodent uterus has previously been reported, we identify for the first time the molecular mechanisms involved and selective effects of androgens on distinct tissue compartments within the uterus. Notably, we describe for the first time that DHT promotes gland formation in the adult mouse uterus through directly stimulating glandular epithelial proliferation and by driving expression of regulators of cell cycle and stromal-epithelial interactions. The novel data generated in the current study provide new insights into the role of androgens in the regulation of endometrial function.

In the uterus, sex steroid action occurs via direct steroid hormone receptor signaling in target cells and indirect paracrine effects on neighboring cellular compartments. Such examples of intercellular paracrine signaling include the stromal-derived secretion of IGF1 and WNT5α binding on epithelial receptors controlling proliferation and gland formation respectively. Thus, regulation of the complex stromal-epithelial interactions resulting from androgen action can be investigated using in vivo model systems, rendering rodents invaluable models. To investigate the impact of androgen treatment in the steroid-depleted mouse uterus, we treated ovx mice with DHT at a supra-physiological dose (0.2 mg/mouse) previously shown to elicit uterine responses (29, 33). Although the DHT concentrations generated in our experimental conditions are above the physiological levels detected in cycling female

Legend to Figure 1 Continued. . .

weight with DHT treatment while after 7 days of treatment the same effect was more pronounced. (B, C, D) Similar effects for a time-dependent increase with DHT treatment were observed in total uterine surface area (B) endometrial area (C) and myometrial area (D). (E) Treatment with DHT resulted in a significant time-dependent decrease in uterine cell density at 24 hrs and 7 days. (F) Representative images of hematoxylin- and eosin-stained mouse uterine cross-sections after steroid treatments. All error bars represent SEM and Student’s unpaired t test was used for statistical analysis comparing VC- and DHT-treated samples of the respective time point (n = 4–8 per treatment group), *P < .05, **P < .01, ***P <.001, ****P < .0001. Scale bar: 500 µm.
mice (6), this dose is consistent with those used in several previous studies investigating the direct action of DHT in the rodent uterus (22, 34) and adipose tissue (29, 35).

In this study, DHT induced a time-dependent increase in uterine weight in agreement with previous reports in rats treated with DHT or the synthetic androgen mibolerone, where a dose- and time-dependent increase in uterine weight after androgen treatment was detected in that species (34). In the present study, increases in total uterine area, endometrial area and myometrial area accompanied by a significant decrease in cell density, possibly due to water imbibition, were detected, demonstrating the trophic effects of DHT in both uterine compartments in the mouse. Although trophic effects are also induced by estrogens in the rodent uterus, in the current study uterine morphology after DHT treatment lacked the characteristic distended phenotype, edema and thinness of the endometrial layer induced by E2 (36, 37) consistent with a unique effect of androgens in regulating uterine physiology that is distinct from that of estrogens. Early studies using in vitro cell-free systems and in vivo rodent models have demonstrated interaction between testosterone and DHT with ER, leading to nuclear translocation of ER, while cotreatment with antiestrogens but not antiandrogens blocked this effect (38, 39). However, a later study demonstrated that the in vivo doses of DHT required to elicit ER cytoplasmic depletion and nuclear translocation in the rat uterus are very high (5–10 mg), suggesting that the uterine trophic effects of DHT observed in our study are unlikely to be mediated by ER (40). In addition, ovariectomized female rats cotreated with DHT and the AR antagonist bicalutamide exhibited a complete suppression of DHT-induced expression of Igf1, a growth factor whose upregulation is both ERα- and AR-controlled (34). This finding together with the fact that putative ERα target-genes are not induced after treatment with DHT in the mouse uterus (34) suggest more of a functional interaction between AR and ERα than a physical one. Notably, in a study describing the development of a uterine glandular epithelial specific ARKO mouse model (ugeARKO), uterine parameters (uterine weight and surface area) of adult ubeARKO female mice were within the normal range but androgen-induced uterine growth in ovx mice was impaired (41) consistent with the results in the present study which describe androgenic induction of uterine growth via epithelial AR.

Since androgens promote growth of the rodent uterus, we investigated expression of proliferation markers in the tissue to elucidate compartment-specific effects. Assessment by immunofluorecence of the proliferation marker MKi67 which detects all actively proliferating cells (cells not in G0 of the cell-cycle) revealed extensive proliferation within the uterine epithelium that was associated

![Figure 2](https://example.com/figure2.png)

Figure 2. Treatment with DHT results in a marked increase of AR immunoreactivity in uterine epithelial cells accompanied by a downregulation of Ar mRNA. (A, C) Expression of AR was restricted to the stromal compartment and the myometrial smooth muscle cells of the vehicle groups at both 24 hrs (A) and 7 days (C) with glandular (black arrowheads) and luminal epithelial AR levels being low to undetectable. (B, D) Treatment with DHT resulted in intense AR immunostaining in the stroma accompanied by expression of AR in the luminal and glandular epithelium after 24 hrs (B, red arrowheads), with the glandular epithelium retaining AR expression after 7 days of DHT treatment (D). (E) Treatment with DHT for 7 days resulted in a significant downregulation of Ar mRNA in the mouse uterus. All error bars represent SEM (n = 8 per treatment group), **P < .01. Scale bars: 100 μm. Neg: negative control.
with a significant increase in concentrations of Mki67 mRNA after 24 hours that was also accompanied by nuclear translocation of cyclin D1 in the epithelium (data not shown). The proliferative effect of DHT was confirmed by assessing incorporation of BrdU, which revealed extensive proliferation in the epithelial compartment but not in the stroma after treatment with DHT. Notably, increased proliferation was only detected after 24 hrs of treatment consistent with DHT inducing rapid changes in the tissue. Our findings are further complemented by Terada et al who reported that treatment of ovx E2-primed mice with DHT significantly decreased the apoptotic index of the uterine epithelium, thus arguing for an inhibitory effect of DHT on cell death on the mouse uterine epithelium (42). Furthermore, the effects of DHT partially mimic those seen after treatment with E2 where maximal epithelial proliferation rate is observed after 21 hrs of E2 treatment followed by a decline in proliferation and increased apoptosis after repeated E2 injections (43).

Treatment of ovx mice with DHT resulted in a striking increase in AR immunoreactivity in the uterine stroma accompanied by induced expression of AR in glandular and luminal epithelial cells. Previous studies have demonstrated that while androgens decrease AR transcription, they positively modulate translation efficiency and stability of the AR protein, thus increasing AR protein levels (44–47). These findings are in agreement with our data where we detected a significant decrease of Ar mRNA following treatment with DHT for 7 days accompanied by an increase of AR protein levels. As already mentioned, previous studies have reported that androgenic effects in the mouse uterus can be mediated via ERα signaling (21, 34), with extensive cross-talk between the two receptors (40, 48). However no change was observed in the expression pattern of ERα after DHT treatment, suggesting that if any functional interaction occurs between AR and ERα following DHT treatment it is not due to altered ERα levels.

Taking together the uterine epithelial proliferation following DHT treatment with the known role of androgens in controlling cell-cycle progression in the prostate (49) and the mouse uterus (22), transcript expression of cell-cycle regulators was analyzed by real-time PCR. The multifunctional cell-cycle regulator Wee1 controls chromatin integrity and entry into mitosis by regulating the transcription of histones and forming active complexes with factors that control cell-cycle progression (reviewed in (50)). DHT induced up-regulation of Wee1 at 24 hrs, consis-

**Figure 3.** Short-term treatment with DHT increases Mki67 expression in uterine epithelial cells. (A, C) VC-treated groups displayed nuclear immunostaining for Mki67 (in red staining) in a small proportion of epithelial cells (arrowheads indicate Mki67-positive epithelial cells) at both 24 hrs (A) and 7 days (C). (B) Treatment with DHT for 24 hrs induced marked expression of Mki67 in the luminal and glandular epithelium, while after 7 days Mki67 staining did not differ from VC-treated groups (D). (E) Real-time PCR revealed a significant increase in Mki67 mRNA levels after DHT treatment at 24 hrs, with no difference observed at 7 days between vehicle and DHT. L=Lumen. All error bars represent SEM (n = 8 per treatment group), ****P < .0001. Scale bars: 200 μm. Neg: negative control.
tent with the actively proliferating epithelial compartment at that time point, while its expression after 7 days of DHT treatment was significantly reduced compared to vehicle control suggesting a negative feedback mechanism restoring tissue proliferation to basal levels. The same expression pattern was observed for Ccnd1 (cyclin D1), whose levels and nuclear localization have been shown to be regulated by E2 in mouse uterine epithelial cells (51). Expression of the cell-cycle inhibitor and tumor suppressor Rb1 was significantly downregulated by DHT at both time points consistent with increased proliferation and growth of the uterus detected in response to DHT. Since the changes seen in uterine size reflect changes in all cellular compartments (including the stroma) further studies are required to investigate whether changes in stromal proliferation occur in response to DHT across other time points post androgen administration. The results of the current study extend previous transcriptional analyses of samples generated from DHT-treated isolated human endometrial stromal cells which demonstrate AR-dependent repression of cell cycle regulators (52) and DHT-dependent decreases in both proliferation and apoptosis (12). Taken together these results suggest androgens may impact on the stromal compartment to inhibit stromal cell apoptosis, rather than promoting proliferation, in addition to the direct effects on the uterine epithelial proliferation described in the current study.

Figure 4. DHT stimulates transient epithelial cell proliferation in both glandular and luminal compartments. (A, B) With VC treatment, BrdU was detected in very few epithelial cells after 24 hrs, while treatment with DHT induced pronounced luminal and glandular epithelial nuclear BrdU incorporation. (C) Quantification of BrdU-positive cells revealed a significant increase of luminal (LE) and glandular (GE) epithelial proliferation with DHT after 24 hrs of treatment. (D, E, F) After 7 days of treatment, proliferation index showed no significant difference between VC and DHT groups. All error bars represent SEM (n = 8 per treatment group), ***P < .001, ****P < .0001. Scale bars: 200 μm. Neg: negative control.

Wnt signaling is a major pathway involved in stromal-epithelial interactions and organ patterning during neonatal and postnatal uterine development. Wnt4 and Wnt5a are expressed by stromal fibroblasts and Wnt7a by epithelial cells with paracrine and autocrine signaling controlling cell fate and differentiation of the uterus (53). We observed significant changes in the expression pattern of these factors, with Wnt4 and Wnt7a being significantly downregulated and Wnt5a significantly upregulated after DHT treatment. Studies with mice have demonstrated that all three Wnts are required for gland formation in the uterus and knockout mice for these Wnts have compromised fertility (54–56). In addition, administration of either progesterone or the synthetic estrogen diethylstilbestrol (DES) during an early postnatal time window inhibits endometrial formation of glands (adenogenesis) in the mouse uterus (3, 57). Similarly, cadherin 1 (Cdh1) has been shown to be vital for endometrial differentiation of the uterine epithelium, while loss of Cdh1 in the uterus leads to absence of glands, a disorganized luminal epithelium and upregulation of Wnt4a with concomitant downregulation of Wnt5a in the neonatal mouse uterus (58). In our study, treatment with DHT induced a significant upregulation of Cdh1 at both 24 hrs and 7 days accompanied by downregulation of Wnt4a and upregulation of Wnt5a, suggesting that androgens in the mouse uterus positively regulate formation of glands.
Trophic effects in tissues are often accompanied by tissue remodelling and that led us to investigate the expression of vinculin (Vcl), an adherens junction component involved in cell-cell adhesion, whose expression is andro-

Figure 5. Treatment with DHT has time-dependent impacts on concentrations of mRNAs encoded by genes implicated in regulation of the cell cycle and stroma-epithelial cross-talk. Real-time PCR analysis of whole-tissue uterine homogenates identified altered expression of cell-cycle regulators and proliferation markers (Wee1 (A), Ccdc1 (B), Rbl1 (C)) and genes involved in stroma-epithelial interactions and epithelial growth factors (Wnt4 (D), Wnt5a (E), Wnt7a (F), Cdh1 (G), Vcl (H), Igf1 (I), Prlb (J), Prlr (K), Foxa2 (L), Fgf8 (M), Hgf (N)). For all RT-PCR analyses n = 8 per treatment group per time point were used and all data were normalized to the housekeeping gene 18s. All error bars represent SEM, *P < .05, **P < .01, ***P < .001, ****P < .0001.
gen-regulated in the prostate (59). Vcl was significantly upregulated after 24 hrs of DHT treatment and by 7 days its expression was the same as the vehicle, indicating an initial phase of alteration in cell adhesion properties followed by restoration to basal levels. In addition, this is the first evidence of androgenic regulation of Vcl in the uterus.

To corroborate the increased epithelial proliferation after treatment with DHT, expression of epithelial growth factors was assessed. IGF1 is predominantly produced by mouse endometrial stromal cells following E2 treatment and signals to the epithelium to proliferate (31) and previous studies have reported that the IGF1 promoter contains androgen response elements (60). In the current study, a significant increase in the expression of the epithelial growth factor Igf1 was detected after 7 days of DHT treatment. Notably, Nantermet et al reported that DHT did not induce uterine hypertrophy in mice lacking a functional estrogen receptor (estrogen receptor α knock-out mice; ERKO), suggesting that ERα is required to mediate DHT responses (34). However, Klotz et al have previously reported that ERα expression is necessary to mediate the proliferative effect of IGF1 in the mouse uterus (61). Thus, taken together with the data in the current study these results are consistent with DHT also mediating indirect effects on proliferation in the uterus through stromal-epithelial cross-talk following induction of the IGF signaling pathway. The stromal-derived epithelial growth factors FGF7 and HGF both mediate stromal-epithelial interactions in the uterus by promoting epithelial proliferation with important roles in epithelial morphogenesis (62). While progesterone administration in the neonatal mouse uterus inhibits uterine gland formation accompanied by a significant reduction in the expression of Fgf7 and a significant increase in the expression of Hgf (62), in our study, treatment with DHT induced the opposite effect by significantly increasing Fgf7 mRNA levels and decreasing Hgf mRNA levels.

The most striking result observed was the impact of DHT on uterine glands. In control uteri, AR expression was not detected in glandular epithelial cells, however DHT treatment induced AR expression and increased glandular epithelial proliferation. Quantification of FOXA2-positive glands demonstrated more uterine glands in the DHT-treated mouse uterus, an effect which was unique to DHT, as treatment with E2 did not produce this effect. FOXA2 is expressed exclusively in the uterine glandular epithelium of mice and Foxa2 uterine knockout mice fail to develop glands (30). In the current study, DHT induced changes in expression of a number of factors that promote adenogenesis in adult mice. Although expression of Foxa2 mRNA in whole tissue homogenates was not significantly different between control and DHT treated mice, treatment with E2 significantly decreased Foxa2 mRNA concentrations highlighting the importance of androgen-estrogen balance in the regulation of this cellular compartment in the uterus. Taken together these data are consistent with DHT regulating gland formation in the adult mouse uterus by inducing a transcriptional program that results in de novo adenogenesis.

In the present study, treatment of mice with DHT revealed androgen-specific effects on endometrial architecture characterized by a rapid increase in proliferation of epithelial cells lining the glands and significant DHT-dependent changes in expression of genes associated with cell-cycle regulation and stromal-epithelial cross-talk. These results suggest that any endocrine pathology that resulted in significant deviation from normal intra-tissue concentrations of androgens could have a long term impact on the abundance of glandu-
lar epithelial cells, with consequent impacts on glandular secretions and the epithelial-stromal cell cross-talk required to support establishment of pregnancy in women.

Acknowledgments

This work was supported by grant G1100356/1 from the Medical Research Council UK (MRC) to Professor Philippa TK Saunders. We thank Frances Collins, Dr Erin Greaves, Mike Millar and Gary Menzies for their technical assistance and scientific input.

The authors have nothing to disclose.

Address all correspondence and requests for reprints to: Professor Philippa Saunders PhD, FmedSci, MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, 47 Little France Crescent, EH16 4TJ, Edinburgh, UK, Phone: 0131-242–6388, Email: P.Saunders@ed.ac.uk

This work was supported by Funding: MRC program grant G1100356/1 to PTKS and a University of Edinburgh Principal’s Career Development PhD studentship to IS.

2Current address: The Ritchie Centre, Hudson Institute of Medical Research, 27–31 Wright Street, 3168, Clayton, Victoria, Australia; Current address.

THE AUTHORS HAVE NOTHING TO DISCLOSE

References

1. Filant J, Spencer TE. Cell-specific transcriptional profiling reveals candidate mechanisms regulating development and function of uterine epithelia in mice. Biol Reprod. 2013;89:86.

2. Simon L, Spiewak KA, Ekmans GC, Kim J, Lydon JP, Bagchi MK, Bagchi IC, DeMayo FJ, Cooke PS. Stromal progesterone receptors mediate induction of Indian Hedgehog (IHH) in uterine epithelium and its downstream targets in uterine stroma. Endocrinology. 2009;150:3871–3876.

3. Hayashi K, Yoshioka S, Reardon SN, Rucker EB, Spencer TE, DeMayo FJ, Lydon JP, MacLean JA. WNTs in the neonatal mouse uterus: potential regulation of endometrial gland development. Biol Reprod. 2011;84:308–319.

4. Pawar S, Starovesky E, Orvis GD, Behringer RR, Bagchi IC, Bagchi MK. STAT3 regulates uterine epithelial remodeling and epithelial-stromal crosstalk during implantation. Mol Endocrinol. 2013;27:1996–2012.

5. Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, Goh VH, Ridgway EC, Wierman ME. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids. 2011;76:177–182.

6. Nilsson ME, Vandenput L, Tivesten Å, Norlén AK, Lagerquist MK, Windahl SH, Börjesson AE, Farman HH, Poutanen M, Benrick A. Measurement of a Comprehensive Sex Steroid Profile in Rodent Serum by High-Sensitive Gas Chromatography-Tandem Mass Spectrometry. Endocrinology. 2015;156:2492–2502.

7. Makieva S, Saunders PT, Norman JE. Androgens in pregnancy: roles in parturition. Hum Reprod Update. 2014;20:542–559.

8. Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod. 2002;66:297–304.

9. Wang F, Pan J, Liu Y, Meng Q, Lv P, Qu F, Ding GL, Klausen C, Leung PC, Chan HC, Yao W, Zhou CY, Shi B, Zhang J, Sheng J, Huang H. Alternative splicing of the androgen receptor in polycystic ovary syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:4743–4748.

10. Huhtinen K, Saloniemi-Heinonen T, Keski-Rahkonen P, Desai R, Laajala D, Stahle M, Hakkinen MR, Aiwosana M, Supitto P, Kujari H, Aittokallio T, Handelsman DJ, Auriola S, Perheentupa A, Poutanen M. Intra-tissue steroid profiling indicates differential progesterone and testosterone metabolism in the endometrium and endometriosis lesions. J Clin Endocrinol Metab. 2014;99:E2188–2197.

11. Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril. 1998;69:682–690.

12. Marshall E, Lowrey J, MacPherson S, Maybin JA, Collins F, Critchley HO, Saunders PT. In silico analysis identifies a novel role for androgens in the regulation of human endometrial apoptosis. J Clin Endocrinol Metab. 2011;96:E1746–1755.

13. Shayan OD, Nayak NR, Burton KA, Chwalisz K, Cameron ST, Critchley HO, Baird DT, Brenner RM. Progestogen antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab. 2001;86:2668–2679.

14. Pelletier G, Luu-The V, Li S, Labrie F. Localization and estrogenic regulation of androgen receptor mRNA expression in the mouse uterus and vagina. J Endocrinol. 2004;180:77–85.

15. Xu J, Li M, Zhang L, Xiong H, Lai L, Guo M, Zong T, Zhang D, Yang B, Wu L, Tang M, Kuang H. Expression and regulation of androgen receptor in the mouse uterus during early pregnancy and decidualization. Mol Reprod Dev. 2015.

16. Dart DA, Waxman J, Aboagye EO, Bevan CL. Visualising androgen receptor activity in male and female mice. PLoS One. 2013;8:e71694.

17. Walters KA, McTavish KJ, Seneviratne MG, Jimenez M, McMahon AC, Allan CM, Salamonsen LA, Handelsman DJ. Subfertile female androgen receptor knockout mice exhibit defects in neuroendocrine signalling, intraovarian function, and uterine development but not uterine function. Endocrinology. 2009;150:3274–3282.

18. Miller N, Bedard YC, Cooter NB, Shaul DL. Histological changes in the genital tract in transsexual women following androgen therapy. Histopathology. 1998;12:661–669.

19. Perrone AM, Cerpolini S, Maria Salhi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P, Ghi T, Pelusi G, Pelusi C, Mergioglia MC. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med. 2009;6:3193–3200.

20. Gibson DA, Simitsidellis I, Collins F, Saunders PT. Evidence of androgen action in endometrial and ovarian cancers. Endocr Relat Cancer. 2014;21:T203–218.

21. Weihua Z, Ekman J, Almkvist A, Saji S, Wang L, Warner M, Gustafsson JA. Involvement of androgen receptor in 17beta-estra- diol-induced cell proliferation in rat uterus. Biol Reprod. 2002;67:616–623.

22. Ivanga M, Labrie F, Calvo E, Belleau P, Martel C, Pelletier G, Morissette J, Labrie F, Durocher F. Fine temporal analysis of DHT transport into the target cell: a potential role for the androgen receptor in the male accessory gland. J Endocrinol. 2002;174:267–273.

23. Soto AM, Sonnenschein C. Estrogen and androstenedione in the regulation of human endometrial apoptosis. J Natl Cancer Inst. 2001;93:1673–1675.

24. Groothuis PG, Dassen HH, Romano A, Punyadeera C. Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human. Hum Reprod Update. 2007;13:405–417.
25. Lee AE. Cell division and DNA synthesis in the mouse uterus during continuous oestrogen treatment. J Endocrinol. 1972;55:507–513.

26. Lee AE, Rogers LA, Trinder G. Changes in cell proliferation rate in mouse uterine epithelium during continuous oestrogen treatment. J Endocrinol. 1974;61:117–121.

27. Geck P, Szelej J, Jimenez J, Lin TM, Sonnenschein C, Soto AM. Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells. The Journal of steroid biochemistry and molecular biology. 1997;63:211–218.

28. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–682.

29. Zhang Y, Calvo E, Martel C, Luu-The V, Labrie F, Tchernof A. Response of the adipose tissue transcriptome to dihydrotestosterone in mice. Physiol Genomics. 2008;35:254–261.

30. Jeong JW, Kwak I, Lee KY, Kim TH, Large MJ, Stewart CL, Kaestner KH, Spence TE. Interactions between androgen and estrogen receptors and the effects on their transactivation properties. Mol Cell Endocrinol. 2000;167:139–150.

31. Filant J, Spencer TE. Endometrial glands are essential for blastocyst implantation and decidualization in the mouse uterus. Biol Reprod. 2011;83:396–403.

32. Spencer TE. Biological roles of uterine glands in pregnancy. Semin Reprod Med. 2014;32:346–357.

33. Azzi L, El-Alfy M, Martel C, Labrie F. Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. J Invest Dermatol. 2005;124:22–27.

34. Nantermet PV, Masarachia P, Gentile MA, Pennypacker B, Xu J, Holder D, Gerhold D, Towler D, Schmidt A, Kimmel DB, Freedman LP, Harada S, Ray WJ. Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways. Endocrinology. 2005;146:564–578.

35. De Giorgio MR, Yoshioka M, St-Amand J. Expression of novel genes linked to the androgen-induced, proliferation of the estrogen receptor. Mol Endocrinol. 2004;18:4944–4974.

36. Miller C, Pavlova A, Sassoon DA. Differential expression patterns of Wnt genes in the murine female reproductive tract during development and the estrous cycle. Mech Dev. 1998;76:91–99.

37. Franco HL, Dai D, Lee KY, Rubel CA, Roop D, Boerboom D, Jeong JW, Lydon JP, Bagchi IC, Bagchi MK, DeMayo FJ. WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during early embryo implantation and decidualization in the mouse. FASEB J. 2011;25:1176–1187.

38. Orangeckay M, Kitajewski J, Sassoon D. Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development. 2004;131:2061–2072.

39. Dunlap KA, Filant J, Hayashi K, Rucker EB, Song G, Deng JM, Behringer RR, DeMayo FJ, Lydon JP, Jeong JW, Spencer TE. Postnatal deletion of Wnt7a inhibits uterine gland morphogenesis and compromises adult fertility in mice. Biol Reprod. 2011;85:386–396.

40. Martin L, Finn CA, Trinder G. Hypertrophy and hyperplasia in the mouse uterus after oestrogen treatment: an autofluorography study. J Endocrinol. 1973;63:133–144.

41. Kronogram A, Wilson CM, Wilson JD, Allman DR, McPhail MJ. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol. 1991;76:79–88.

42. Wolf DA, Herzinger T, Hernecking H, Blaschke D, Hörz W. Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol Endocrinol. 1993;7:924–936.

43. Zhou ZX, Lane MV, Kemptainen JA, French FS, Wilson EM. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol. 1995;9:208–218.

44. Yeap BB, Krueger RG, Leedman PJ. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology. 1999;140:3282–3291.

45. Kammen J, Kammen NP. WEE1 tyrosine kinase, a novel epigenetic modifier. Trends Genet. 2013;29:394–402.

46. Zhu L, Pollard JW. Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor I signaling. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:15847–15851.

47. Cloke B, Huthinen K, Fusi L, Kajihara T, Yliekkila M, Ho KK, Teklenburg G, Lavery S, Jones MC, Trew G, Kim JJ, Lam EW, Cartwright JE, Poutanen M, Brosens JJ. The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium. Endocrinology. 2008;149:464–472.

48. Miller C, Pavlova A, Sassoon DA. Differential expression patterns of Wnt genes in the murine female reproductive tract during development and the estrous cycle. Mech Dev. 1998;76:91–99.

49. Francois HL, Dai D, Lee KY, Rubela CA, Roop D, Boerboom D, Jeong JW, Lydon JP, Bagchi IC, Bagchi MK, DeMayo FJ. WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during early embryo implantation and decidualization in the mouse. FASEB J. 2011;25:1176–1187.

50. Mericskay M, Kitajewski J, Sassoon D. Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development. 2004;131:2061–2072.

51. Dunlap KA, Filant J, Hayashi K, Rucker EB, Song G, Deng JM, Behringer RR, DeMayo FJ, Lydon JP, Jeong JW, Spencer TE. Postnatal deletion of Wnt7a inhibits uterine gland morphogenesis and compromises adult fertility in mice. Biol Reprod. 2011;85:386–396.

52. Filant J, Zhou H, Spencer TE. Progesterone inhibits uterine gland development in the neonatal mouse uterus. Biol Reprod. 2012;86:146–149.

53. Reardon SN, King ML, MacLean JA, Mann JLA, DeMayo FJ, Lydon JP, Hayashi K. CDH1 is essential for endometrial differentiation, gland development, and adult function in the mouse uterus. Biol Reprod. 2012;86:141–110.

54. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22:2790–2799.

55. Wu Y, Zhao W, Zhao J, Pan J, Wu Q, Zhang Y, Bauman WA, Cardozo CP. Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology. 2007;148:2984–2993.

56. Klotsz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, Maggi A, DiAugustine RP, Korah KS. Requirement of estrogen
receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor crosstalk. J Biol Chem. 2002;277:8531–8537.

62. Gray CA, Bartol FF, Tarleton BJ, Wiley AA, Johnson GA, Bazer FW, Spencer TE. Developmental biology of uterine glands. Biol Reprod. 2001;65:1311–1323.